Market Place
Market Place
Post Enquiry
FDA steps in to address challenges faced by cell and gene therapies
The year 2023 was a rather
tough one for cell and gene therapy (CGT) companies. There was news abou
FDA approvals rise 49% in 2023; CRISPR’s gene editing therapy sees light of day
In 2022, when the
US Food and Drug Administration (FDA) was reeling under the impact of the
pandem
Pfizer’s buyout of Seagen, drugmakers suing US govt, obesity drugs make it to top 10 Phispers of 2023
Every week,
PharmaCompass compiles important developments in the world of pharmaceuticals
and brin
